Latest News & Updates

FDA warns about possible increased risk of death and serious side effects with cancer drug Copiktra (duvelisib)
June 30, 2022

Continue Reading »

FDA approves lisocabtagene maraleucel for second-line treatment of large B-cell lymphoma
June 27, 2022

Continue Reading »

FDA grants accelerated approval to dabrafenib in combination with trametinib for unresectable or metastatic solid tumors with BRAF V600E mutation
June 23, 2022

Continue Reading »

FDA approves Opdivo in combination with chemotherapy and Opdivo in combination with Yervoy for first-line esophageal squamous cell carcinoma indications
June 1, 2022

Continue Reading »

FDA warns about possible increased risk of death and serious side effects with cancer drug Copiktra (duvelisib)
June 30, 2022

Continue Reading »

FDA approves lisocabtagene maraleucel for second-line treatment of large B-cell lymphoma
June 27, 2022

Continue Reading »

FDA grants accelerated approval to dabrafenib in combination with trametinib for unresectable or metastatic solid tumors with BRAF V600E mutation
June 23, 2022

Continue Reading »

FDA approves Opdivo in combination with chemotherapy and Opdivo in combination with Yervoy for first-line esophageal squamous cell carcinoma indications
June 1, 2022

Continue Reading »

Get More from FLASCO With Your Membership

The Corporate Membership Program allows FLASCO to expand our offerings to our membership. Every FLASCO meeting also provides the industry representative with opportunities to educate our members. When you send representatives to a FLASCO meeting, you are allowing them to share their knowledge, as well as receive the same knowledge as our members by participating within the educational sessions. This helps ensure that the hematology and oncology community at large are learning, sharing best practices, and finding solutions to problems together.

Corporate Members:

Diamond Elite

Diamond

Platinum

Gold

We're Here to Help Contact Us

Contact Us

Add your name, email & message below: